Cancer diagnostics and therapeutics company Microlin Bio files for a $25 million IPO


Shutterstock photo

Microlin Bio, a development stage diagnostic and therapeutics company focusing on microRNA and its role in oncology, filed on Friday with the SEC to raise up to $25 million in an initial public offering. The company was founded in July 2013 by Joseph Hernandez, a biotech entrepreneur that previously founded Prolias Technologies and Innovative Biosensors. Earlier in his career, Mr. Hernandez spent time at Digene (subsequently acquired by Qiagen), Affymetrix and Merck. He is the largest shareholder of Microlin Bio with a 93% ownership stake pre-IPO.

The New York, NY-based company plans to list on the NASDAQ under the symbol MCLB. Sunrise Securities is the sole bookrunner on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks:

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by